Biosimilars Forum Applauds President Trump for Signing the FDA Reauthorization Act

Washington, D.C., August 19, 2017 – Today, the Biosimilars Forum issued the following statement about President Trump signing the Food and Drug Administration Reauthorization Act (FDARA):

The Biosimilars Forum thanks Congress and President Trump for passing and quickly signing the Food and Drug Administration Reauthorization Act (FDARA), which will give the FDA the resources it needs to review and approve new biosimilar drugs. Now that FDA’s user fee programs have been reauthorized, we urge the agency to work with Congress and the Administration to ensure that the biosimilars market remains vibrant and gives patients access to the crucial therapies they need.

“We urge the Administration to continue its support of biosimilars by modifying current Medicare reimbursement policy to be consistent with FDA’s regulatory policy and provide each biosimilar with its own unique, individualized billing code.

About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit, or go to Facebook/USBiosimilars to follow related conversations and join the dialogue.

Aimee Steel Lubin